



August 07, 2025

Ref: - GH/2025-26/EXCH/40

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA


Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Dear Sir(s),

We would like to inform you that the Board of Directors of Global Health Limited ('GHL/Company') at its meeting held today i.e. Thursday, August 07, 2025, has *inter alia*, approved:

1. Unaudited Standalone and Consolidated Financial Results of the Company for the First Quarter ended June 30, 2025 ('Results');
The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandio & Co LLP, Chartered Accountants thereon, are enclosed herewith as **Exhibit** pursuant to Regulation 33 of the Listing Regulations.
2. Notice of 21st Annual General Meeting (AGM) of the Company to be held on *Friday, September 19, 2025 at 12:00 Noon* through Video Conferencing/Other Audio Video Means ('VC/OAVM') Facility.
3. Pursuant to Regulation 42 of Listing Regulations, has fixed the record date for the purpose of determining entitlement of the shareholders for the payment of final dividend for the financial year 2024-25, which shall be paid to the shareholders within 30 days from the date of declaration, if declared by the shareholders at the 21st AGM.

Symbol	Type of Security	Record date for payment of dividend	Purpose
NSE: MEDANTA BSE: 543654	Equity	Friday, August 22, 2025	Payment of final dividend of Rs. 0.50/- per equity share for the financial year 2024-25, subject to approval of the shareholders at the ensuing AGM.





4. Based on the recommendation of the Nomination & Remuneration Committee, recommended the re-appointment of the following:
 - a) Dr. Naresh Trehan (DIN-00012148) as Chairman and Managing Director of the Company ('CMD'), not liable to retire by rotation and Chairman – Heart Institute & Chief Cardiac Surgeon for a period of 5 (five) years w.e.f. August 01, 2026. The requisite details under the Listing Regulations is annexed herewith as **Annexure A**.
 - b) Mr. Vikram Singh Mehta (DIN: 00041197) as an Independent Director of the Company for second term of 5 (five) consecutive years w.e.f. January 25, 2026. The requisite details under the Listing Regulations is annexed herewith as **Annexure B**.
 - c) Mr. Hari Shanker Bhartia (DIN: 00010499) as an Independent Director of the Company for second term of 5 (five) consecutive years w.e.f. March 23, 2026. The requisite details under the Listing Regulations is annexed herewith as **Annexure C**.
5. Based on the recommendation of the Audit Committee, recommended the appointment of M/s MAKES & CO., Company Secretaries in Practice, (FRN: P2018UP067700 & Peer Review Certificate No. 2064/2022), as Secretarial Auditors of the Company for a period of 5 (five) consecutive years starting from FY 2025-26, to the shareholders for their approval at the ensuing AGM. The requisite details under the Listing Regulations is annexed herewith as **Annexure D**.


The Trading Window will open after 48 hours from the declaration of above Results, to the Stock Exchanges.

The meeting of the Board of Directors commenced at 2.00 P.M. and concluded at 3:50 P.M

Thanking You,

For Global Health Limited

Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035
Encl: a/a



Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023



Annexure A

S. No.	Particulars	Information of event
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-appointment
2.	Date of appointment/ re-appointment/cessation (as applicable) & term of appointment/ re-appointment	Re-appointment of Dr. Naresh Trehan as Chairman & Managing Director and Chairman – Heart Institute & Chief Cardiac Surgeon of the Company for a period of 5 (five) years w.e.f. August 01, 2026, subject to approval of the shareholders.
3.	Brief profile (in case of appointment)	Dr. Trehan is the Chairman and Managing Director of the Company. He was appointed on the Board of the Company on August 13, 2004. He has been the Chairman and Managing Director of the Company since June 01, 2007 and was re-appointed on August 01, 2021. He is the Promoter and has also been appointed as the Chairman - Heart Institute & Chief Cardiac Surgeon. He holds a bachelor's degree in medicine and surgery from the Faculty of Medicine, University of Lucknow and has been awarded a certificate in speciality of thoracic and cardiac surgery by the American Board of Thoracic Surgery. He has served in the training programme and as the 'Fellow in Thoracic Surgery' at the New York University Medical Centre at Bellevue Hospital, University Hospital and Manhattan V.A. Hospital, New York, USA. He is also an elected fellow of the American Society of Angiology and the Indian Association of Cardiovascular-thoracic Surgeons. He has been admitted to honorary fellowship of the Royal Australasian College of Surgeons in 2000. He has been awarded the academic title of 'Honorary Professor' of the National Scientific Research Medical Center Joint Stock Company, the Republic of Kazakhstan. He has been awarded the 'Padma Bhushan' in 2001 and the 'Padma Shri' in 1991 by the Government of India and Dr. B.C. Roy Award by Medical Council of India in 2005. He has also been awarded a special award dated November 14, 2021 by the American Association of Cardiologists of Indian Origin for his outstanding contributions as 'Indian Father of Cardiac Surgery'.
4.	Disclosure of relationships between directors (in case of appointment of a Director)	Dr. Trehan is related to Mr. Pankaj Sahni, Group CEO & Director of the Company.

5.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018- 19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/ 24, both dated 20 June 2018	Dr. Trehan is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.
----	--	---


Annexure B

S. No.	Particulars	Information of event
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-appointment
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/ re-appointment	Re-appointment of Mr. Vikram Singh Mehta as a Non-Executive Independent Director of the Company for a second term of 5 (five) consecutive years w.e.f. January 25, 2026, subject to approval of the shareholders.
3.	Brief profile (in case of appointment)	Mr. Mehta is a Non-Executive Independent Director of the Company. He was appointed on the Board on January 25, 2021. He holds a bachelor's degree in arts (Politics and Economics Honors) from the University of Oxford, United Kingdom. He currently serves as chairman and distinguished fellow at Centre for Social and Economic Progress and independent director on the boards of various companies including Colgate-Palmolive (India) Limited and Apollo Tyres Limited. He also received Asia Centre for Corporate Governance and Sustainability's Award for 'Best Independent Director' in India for 2016.
4.	Disclosure of relationships between directors (in case of appointment of a Director)	Mr. Mehta is not related to any Director of the Company.
5.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018- 19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/ 24, both dated 20 June 2018	Mr. Mehta is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.




Annexure C

S. No.	Particulars	Information of event
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Re-appointment
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/ re-appointment	Re-appointment of Mr. Hari Shanker Bhartia as a Non-Executive Independent Director of the Company for a second term of 5 (five) consecutive years w.e.f. March 23, 2026 subject to approval of the shareholders.
3.	Brief profile (in case of appointment);	Mr. Bhartia is a Non-Executive Independent Director of the Company. He was appointed on the Board on March 23, 2021. He holds a bachelor's degree in technology in chemical engineering from the Indian Institute of Technology, Delhi. He has over 38 years of experience in the pharmaceuticals, life science and food service industries. He currently serves as co-chairman and managing director at Jubilant Pharmova Limited. He was awarded the 'Distinguished Alumni Award' by the Indian Institute of Technology, Delhi in 2000.
4.	Disclosure of relationships between directors (in case of appointment of a Director).	Mr. Bhartia is not related to any Director of the Company.
5.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018- 19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/ 24, both dated 20 June 2018	Mr. Bhartia is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.



Annexure D

S. No.	Particulars	Information of event
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Based on the recommendation of the Audit Committee, the Board of Directors in terms of Regulation 24A of Listing Regulations, has recommended appointment of MAK & CO., Companies Secretaries, bearing firm registration number P2018UP067700, as Secretarial Auditors of the Company for a period of 5 (five) consecutive years commencing from FY 2025-26, for approval of the shareholders at the ensuing AGM.
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	Term of 5 (Five) consecutive years commencing from the financial year 2025-26.
3.	Brief profile (in case of appointment)	<p>MAK & CO., Companies Secretaries, bearing firm registration number P2018UP067700 and Peer Review Certificate No.: 2064/2022, is partnership firm of practicing company secretaries. MAK & CO. is a corporate consultancy business solution firm which has been promoted, and is managed by, qualified, experienced professionals from the fields of corporate governance and compliance. The partners are experienced company secretaries with collective work experience of over 60 years.</p> <p>MAK, as a professional company secretary firm engaged in providing comprehensive professional services in corporate law, SEBI regulations, FEMA compliance, NBFC Compliances, and allied fields, delivering strategic solutions to ensure regulatory adherence including but not limited to representing corporates before various regulatory authorities.</p>
4.	Disclosure of relationships between directors (in case of appointment of a Director)	Not applicable



Walker ChandioK & Co LLP

21st Floor, DLF Square
Jacaranda Marg, DLF Phase II,
Gurugram - 122 002
Haryana, India

T +91 124 462 8099

F +91 124 462 8001

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Global Health Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Global Health Limited ('the Company') which includes GHL Employee Welfare Trust ('the Trust') for the quarter ended 30 June 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Walker ChandioK & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker Chandiok & Co LLP

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

5. We draw attention to note 4 to the accompanying Statement which describes that a Scheme of Arrangement (the 'Scheme') entered into between the Company and Medanta Holdings Private Limited, an erstwhile wholly-owned subsidiary of the Company, has been approved by the National Company Law Tribunal, New Delhi, vide order dated 20 February 2025. As per such Scheme, the subsidiary has been amalgamated with the Company with effect from the appointed date of the Scheme, being 01 April 2024. The aforesaid Scheme has been given accounting effect in the accompanying Statement in accordance with Appendix C to Ind AS 103, Business Combination of Entities Under Common Control, as prescribed in the Scheme, and consequently, comparative financial information of the prior period presented in the Statement have been restated, the impact of which is further detailed in the said note.

Our conclusion is not modified in respect of this matter.

6. The Statement includes the interim financial information of the Trust, which have not been reviewed, and whose interim financial information reflects total revenues of ₹ Nil, total net profit after tax of ₹ Nil, total comprehensive income of ₹ Nil for the quarter ended 30 June 2025 respectively, as considered in the Statement. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the Trust, is based solely on such unreviewed financial information. According to the information and explanations given to us by the management, this interim financial information is not material to the Company.

Our conclusion is not modified in respect of this matter with respect to our reliance on the aforesaid financial information certified by the Board of Directors.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Tarun Gupta

Partner

Membership No. 507892



UDIN: 25507892BMNSOM2079

Place: Gurugram

Date: 07 August 2025

Global Health Limited

Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India

Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India

CIN:L85110DL2004PLC128319

Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: <https://www.medanta.org>

Statement of standalone unaudited financial results for the quarter ended 30 June 2025

(₹ in millions, unless otherwise stated)

S No.	Particulars	Quarter ended			Year ended
		30 June 2025	31 March 2025	30 June 2024	31 March 2025
		Unaudited	(Refer note 9)	Unaudited (Restated) (Refer note 4)	Audited
	Income				
I	Revenue from operations	8,821.56	8,028.68	7,578.62	32,041.46
II	Other income	231.39	256.66	245.39	909.29
	Total income	9,052.95	8,285.34	7,824.01	32,950.75
III	Expenses				
	Cost of materials consumed	1,921.63	1,723.75	1,714.57	7,158.13
	Purchases of stock-in-trade	25.59	58.23	116.91	403.90
	Changes in inventories of stock-in-trade	39.61	32.07	(5.24)	26.24
	Employee benefits expense	2,329.45	1,854.16	1,824.67	7,462.91
	Finance costs	56.58	70.99	101.81	333.91
	Depreciation and amortisation expense	334.08	379.80	360.29	1,496.11
	Retainers and consultants fee	1,092.81	1,064.64	955.49	4,038.72
	Other expenses	1,466.66	1,343.87	1,289.27	5,301.40
	Total expenses	7,266.41	6,527.51	6,357.77	26,221.32
IV	Profit before exceptional item and tax	1,786.54	1,757.83	1,466.24	6,729.43
	Exceptional item (refer note 5)	(195.92)	498.96	-	498.96
V	Profit before tax	1,982.46	1,258.87	1,466.24	6,230.47
VI	Tax expenses				
	Current tax	413.27	361.77	364.21	1,608.65
	Tax pertaining to earlier years	-	6.88	-	6.88
	Deferred tax charge/(credit)	49.55	(43.90)	16.52	(0.34)
VII	Profit after tax	1,519.64	934.12	1,085.51	4,615.28
VIII	Other comprehensive income				
	(i) Items that will not be reclassified to statement of profit or loss	3.01	(30.20)	(26.56)	(12.94)
	(ii) Income-tax relating to items that will not be reclassified to statement of profit or loss	(0.76)	7.60	6.69	3.26
	Total other comprehensive income	2.25	(22.60)	(19.87)	(9.68)
IX	Total comprehensive income	1,521.89	911.52	1,065.64	4,605.60
X	Paid-up equity share capital (face value of ₹ 2 each)	537.54	537.17	537.01	537.17
XI	Reserves (other equity)				34,438.91
XII	Earnings per share (face value of ₹ 2 each) (not annualised for the quarters)				
	Basic (₹ per share)	5.66	3.48	4.04	17.18
	Diluted (₹ per share)	5.65	3.48	4.04	17.18

See accompanying notes to the standalone unaudited financial results



Global Health Limited**Notes to the standalone unaudited financial results:**

- 1 The above standalone financial results of Global Health Limited ('the Company') for the quarter ended on 30 June 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 07 August 2025 and a limited review of the same has been carried out by the statutory auditors.
- 2 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as
- 3 The Chief Operating Decision Maker (CODM) examines the Company's performance from a service perspective and has identified the Healthcare services as single business segment.
- 4 The Board of Directors of the Company ("Board") at its meeting held on 21 March 2024, had approved the Scheme of amalgamation ("the Scheme") of Medanta Holdings Private Limited (wholly-owned subsidiary) with the Company, subject to all the necessary statutory / regulatory approvals.

The Scheme had been approved by the Hon'ble National Company Law Tribunal ('NCLT') vide Order dated 20 February 2025 with appointed date being 01 April 2024. The Scheme became effective on 01 March 2025 upon filing of the certified true copy of the Order with the Registrar of Companies, NCLT of Delhi & Haryana with effect from appointed date.

Accordingly, the Company had accounted for the business combination transaction in accordance the accounting treatment prescribed by the Scheme which is consistent with the principles of Appendix C of Ind AS 103 'Business Combinations under Common Control'. Pursuant to above, the comparative financial information of the Company in respect of the prior period has been restated as if the aforesaid business combination had occurred from the beginning of the preceding period, irrespective of the actual date of the combination. The impact of the amalgamation on the previous period is as under:

Particulars	(₹ in millions, unless otherwise stated)		
	As per published financial results for the quarter ended 30 June 2024	Adjustments on account of amalgamation	Post amalgamation for the quarter ended 30 June 2024 (Restated)
Revenue from operations	6,114.49	1,464.13	7,578.62
Profit before tax	1,297.43	168.81	1,466.24
Profit after tax	962.84	122.67	1,085.51
Earnings per share (₹ per share)	3.58	0.46	4.04

- 5.a Exceptional item for the quarter ended 30 June 2025 represents reversal of interest liability on Export Promotion Capital Goods (EPCG) amounting to ₹ 195.92 millions. Pursuant to the filing of merger order with Registrar of Companies (ROC) the EPCG licenses have been transferred from Medanta Holdings Private Limited to the Company. Considering the internal assessment done by the Company, the management is of the view that the required export obligation will be achieved within the prescribed timeline.
- b Exceptional item for the quarter and year ended 31 March 2025 represents stamp duty amounting to ₹ 498.96 millions payable on the merger of Medanta Holdings Private Limited and the Company.
- 6 During the quarter ended 30 June 2025, the Company received an offer from Assam Electricity Grid Corporation Limited (AEGCL), a Government of Assam undertaking, to acquire a land parcel in Guwahati, Assam for the purpose of establishing a super speciality hospital. The Board of Directors of the Company approved the acquisition of the land parcel on 28 April 2025.

Subsequent to the quarter ended 30 June 2025, the Company has received a letter from the Government of Assam, offering a substitute land parcel measuring 3.5 acres, in place of the originally proposed 3-acre parcel from AEGCL. This substitution has been made following the Company's request for a more suitable location.



Global Health Limited**Notes to the standalone unaudited financial results:**

- 7 The Board of Directors and the shareholders of the Company on 14 November 2024 and 27 December 2024 respectively, approved Global Health Limited Employees Long-Term Share Based Incentive Plan – 2024 (“GHL LTIP 2024 Plan”) for eligible employees of the Holding Company and its subsidiaries and associates. Under the GHL LTIP 2024 Plan, being implemented through a Trust, the maximum number of shares that may be allotted shall not exceed 1,750,000 equity shares of ₹ 2 each through primary issuance and 5,370,147 equity shares (i.e. 2% of paid up capital of the Holding Company as on 31 March 2024), through secondary acquisition.

During the quarter ended 30 June 2025, the Board of Directors of the Company has approved the Grant of 595,500 Options to certain eligible employees and allotted 163,000 shares to GHL Employees Welfare Trust under Part –A and Part- B respectively of GHL LTIP 2024 Plan.

Employee benefits expense includes:**(₹ in millions)**

Particulars	Quarter ended			Year ended
	30 June 2025	31 March 2025	30 June 2024	31 March 2025
	Unaudited	(Refer note 9)	Unaudited (Restated) (Refer note 4)	Audited
Employee share based payment expense	75.72	-	-	-


- 8 The unaudited standalone financial results also include the financial information of GHL Employee Welfare Trust.
- 9 The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures for the full financial year and the unaudited figures up to the nine months ended 31 December 2024, which were subjected to limited review by the statutory auditors.
- 10 Previous period figures have been regrouped/reclassified to conform to the current period's classification.

For and on behalf of the Board of Directors of Global Health Limited

Place : Gurugram

Date : 07 August 2025




Dr. Naresh Trehan
 Chairman and Managing Director

Walker Chandiok & Co LLP

21st Floor, DLF Square
Jacaranda Marg, DLF Phase II,
Gurugram - 122 002
Haryana, India

T +91 124 462 8099
F +91 124 462 8001

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Global Health Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 30 June 2025 being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker ChandioK & Co LLP

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker ChandioK & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Tarun

Tarun Gupta

Partner

Membership No. 507892



UDIN: 25507892BMNSON4753

Place: Gurugram

Date: 07 August 2025

Walker ChandioK &Co LLP

Annexure-1 Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

List of entities included in the Statement

S. No.	Name	Relationship with the Holding Company
1	Global Health Patliputra Private Limited	Wholly owned subsidiary
2	GHL Pharma & Diagnostic Private Limited	Wholly owned subsidiary
3	GHL Hospital Limited	Subsidiary
4	Global Health Institute of Medical Sciences Foundation	Wholly owned subsidiary



Global Health Limited

Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India

Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India

CIN:L85110DL2004PLC128319

Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: <https://www.medanta.org>

Statement of consolidated unaudited financial results for the quarter ended 30 June 2025

(₹ in millions, unless otherwise stated)

S. No.	Particulars	Quarter ended			Year ended
		30 June 2025	31 March 2025	30 June 2024	31 March 2025
		Unaudited	(Refer note 8)	Unaudited	Audited
	Income				
I	Revenue from operations	10,308.37	9,312.47	8,610.77	36,923.15
II	Other income	204.57	229.30	219.27	790.97
	Total income	10,512.94	9,541.77	8,830.04	37,714.12
	Expenses				
III	Cost of materials consumed	2,130.77	1,914.79	1,876.05	7,899.60
	Purchases of stock-in-trade	317.90	205.11	230.97	924.61
	Changes in inventories of stock-in-trade	(58.10)	16.29	(18.38)	(27.52)
	Employee benefits expense	2,564.04	2,040.54	2,011.85	8,245.42
	Finance costs	137.85	150.30	179.79	652.59
	Depreciation and amortisation expense	451.08	492.54	466.18	1,937.48
	Retainers and consultants fee	1,367.00	1,315.92	1,184.79	4,973.43
	Other expenses	1,716.91	1,572.94	1,462.27	6,136.98
	Total expenses	8,627.45	7,708.43	7,393.52	30,742.59
IV	Profit before exceptional item and tax	1,885.49	1,833.34	1,436.52	6,971.53
	Exceptional item (refer note 5)	(195.92)	498.96	-	498.96
V	Profit before tax	2,081.41	1,334.38	1,436.52	6,472.57
	Tax expenses				
	Current tax	413.27	361.77	364.21	1,608.65
	Tax pertaining to earlier years	-	6.88	-	6.88
	Deferred tax charge/(credit)	78.32	(48.05)	9.67	43.86
VI	Profit after tax	1,589.82	1,013.78	1,062.64	4,813.18
VII	Other comprehensive income				
	(i) Items that will not be reclassified to statement of profit or loss	3.11	(30.46)	(27.10)	(9.13)
	(ii) Income-tax relating to items that will not be reclassified to statement of profit or loss	(0.78)	7.72	6.83	2.43
	Total other comprehensive income	2.33	(22.74)	(20.27)	(6.70)
VIII	Total comprehensive income	1,592.15	991.04	1,042.37	4,806.48
	Profit after tax attributable to:				
	(i) Owners of the Holding Company	1,590.09	1,014.00	1,062.86	4,814.37
	(ii) Non-controlling interests	(0.27)	(0.22)	(0.22)	(1.19)
	Other comprehensive income attributable to:				
	(i) Owners of the Holding Company	2.33	(22.74)	(20.27)	(6.70)
	(ii) Non-controlling interests	-	-	-	-
	Total comprehensive income attributable to:				
	(i) Owners of the Holding Company	1,592.42	991.26	1,042.59	4,807.67
	(ii) Non-controlling interests	(0.27)	(0.22)	(0.22)	(1.19)
IX	Paid-up equity share capital (face value of ₹ 2 each)	537.54	537.17	537.01	537.17
X	Reserves (other equity)				33,326.93
XI	Earnings per share (face value of ₹ 2 each) (not annualised for the quarters)				
	Basic (₹ per share)	5.92	3.77	3.96	17.92
	Diluted (₹ per share)	5.91	3.77	3.96	17.92

See accompanying notes to the consolidated unaudited financial results



Global Health Limited**Notes to the consolidated unaudited financial results:**

- 1 The above consolidated financial results of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred as 'the Group') for the quarter ended 30 June 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 07 August 2025 and a limited review of the same has been carried out by the statutory auditors.
- 2 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).
- 3 The Chief Operating Decision Maker (CODM) examines the Group's performance from a service perspective and has identified the Healthcare services as single business segment.
- 4 The Board of Directors of the Holding Company at its meeting held on 21 March 2024, had approved the Scheme of amalgamation ("the Scheme") of Medanta Holdings Private Limited (wholly-owned subsidiary) with the Holding Company, subject to all the necessary statutory / regulatory approvals.

The Scheme had been approved by the Hon'ble National Company Law Tribunal ('NCLT') vide Order dated 20 February 2025 with appointed date being 01 April 2024. The Scheme became effective on 01 March 2025 upon filing of the certified true copy of the Order with the Registrar of Companies, NCLT of Delhi & Haryana with effect from appointed date.

- 5.a Exceptional item for the quarter ended 30 June 2025 represents reversal of interest liability on Export Promotion Capital Goods (EPCG) amounting to ₹ 195.92 millions. Pursuant to the filing of merger order with Registrar of Companies (ROC) the EPCG licenses have been transferred from Medanta Holdings Private Limited to the Holding Company. Considering the internal assessment done by the Holding Company, the management is of the view that the required export obligation will be achieved within the prescribed timeline.
- b. Exceptional item for the quarter and year ended 31 March 2025 represents stamp duty amounting to ₹ 498.96 millions payable on the merger of Medanta Holdings Private Limited and the Holding Company.
- 6 During the quarter ended 30 June 2025, the Holding Company received an offer from Assam Electricity Grid Corporation Limited (AEGCL), a Government of Assam undertaking, to acquire a land parcel in Guwahati, Assam for the purpose of establishing a super speciality hospital. The Board of Directors of the Holding Company approved the acquisition of the land parcel on 28 April 2025.

Subsequent to the quarter ended 30 June 2025, the Holding Company has received a letter from the Government of Assam, offering a substitute land parcel measuring 3.5 acres, in place of the originally proposed 3-acre parcel from AEGCL. This substitution has been made following the Holding Company's request for a more suitable location.

- 7 The Board of Directors and the shareholders of the Holding Company on 14 November 2024 and 27 December 2024 respectively, approved Global Health Limited Employees Long-Term Share Based Incentive Plan – 2024 ("GHL LTIP 2024 Plan") for eligible employees of the Holding Company and its subsidiaries and associates. Under the GHL LTIP 2024 Plan, being implemented through a Trust, the maximum number of shares that may be allotted shall not exceed 1,750,000 equity shares of ₹ 2 each through primary issuance and 5,370,147 equity shares (i.e. 2% of paid up capital of the Holding Company as on 31 March 2024), through secondary acquisition.

During the quarter ended 30 June 2025, the Board of Directors of the Holding Company has approved the Grant of 595,500 Options to certain eligible employees and allotted 163,000 shares to GHL Employees Welfare Trust under Part- A and Part- B respectively of GHL LTIP 2024 Plan.

Employee benefits expense includes:**(₹ in millions)**

Particulars	Quarter ended			Year ended
	30 June 2025	31 March 2025	30 June 2024	31 March 2025
	Unaudited	(Refer note 8)	Unaudited	Audited
Employee share based payment expense	78.77	-	-	-



Global Health Limited


Notes to the consolidated unaudited financial results:

- 8 The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures for the full financial year and the unaudited figures up to the nine months ended 31 December 2024, which were subjected to limited review by the statutory auditors.
- 9 Previous period figures have been regrouped/reclassified to conform to the current period's classification.

For and on behalf of the Board of Directors of Global Health Limited

Place : Gurugram

Date : 07 August 2025



Dr. Naresh Trehan
Chairman and Managing Director